Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 80

1.

Study protocol: Randomized controlled trial of web-based decision support tools for high-risk women and healthcare providers to increase breast cancer chemoprevention.

Crew KD, Silverman TB, Vanegas A, Trivedi MS, Dimond J, Mata J, Sin M, Jones T, Terry MB, Tsai WY, Kukafka R.

Contemp Clin Trials Commun. 2019 Aug 22;16:100433. doi: 10.1016/j.conctc.2019.100433. eCollection 2019 Dec.

2.

Understanding Factors Associated with Uptake of BRCA1/2 Genetic Testing among Orthodox Jewish Women in the USA Using a Mixed-Methods Approach.

Trivedi MS, Colbeth H, Yi H, Vanegas A, Starck R, Chung WK, Appelbaum PS, Kukafka R, Schechter I, Crew KD.

Public Health Genomics. 2018;21(5-6):186-196. doi: 10.1159/000499852. Epub 2019 Jun 4.

PMID:
31163445
3.

Randomized Double-Blind Placebo-Controlled Biomarker Modulation Study of Vitamin D Supplementation in Premenopausal Women at High Risk for Breast Cancer (SWOG S0812).

Crew KD, Anderson GL, Hershman DL, Terry MB, Tehranifar P, Lew DL, Yee M, Brown EA, Kairouz SS, Kuwajerwala N, Bevers T, Doster JE, Zarwan C, Kruper L, Minasian LM, Ford L, Arun B, Neuhouser M, Goodman GE, Brown PH.

Cancer Prev Res (Phila). 2019 Jul;12(7):481-490. doi: 10.1158/1940-6207.CAPR-18-0444. Epub 2019 May 28.

PMID:
31138522
4.

Uptake of genetic testing for germline BRCA1/2 pathogenic variants in a predominantly Hispanic population.

McGuinness JE, Trivedi MS, Silverman T, Marte A, Mata J, Kukafka R, Crew KD.

Cancer Genet. 2019 Jun;235-236:72-76. doi: 10.1016/j.cancergen.2019.04.063. Epub 2019 Apr 24.

PMID:
31078448
5.

Correction: Evaluation of the cost and effectiveness of diverse recruitment methods for a genetic screening study.

Rasouly HM, Wynn J, Marasa M, Reingold R, Chatterjee D, Kapoor S, Piva S, Kil BH, Mu X, Alvarez M, Nestor J, Mehl K, Revah-Politi A, Lippa N, Ernst ME, Bier L, Espinal A, Haser B, Sinha A, Halim I, Fasel D, Cuneo N, Thompson JJ, Verbitsky M, Cohn EG, Goldman J, Marder K, Klitzman RL, Orjuela MA, So YS, Fedotov A, Crew KD, Kiryluk K, Appelbaum PS, Weng C, Siegel K, Gharavi AG, Chung WK.

Genet Med. 2019 May 1. doi: 10.1038/s41436-019-0528-8. [Epub ahead of print]

PMID:
31040387
6.

Evaluation of the cost and effectiveness of diverse recruitment methods for a genetic screening study.

Milo Rasouly H, Wynn J, Marasa M, Reingold R, Chatterjee D, Kapoor S, Piva S, Kil BH, Mu X, Alvarez M, Nestor J, Mehl K, Revah-Politi A, Lippa N, Ernst ME, Bier L, Espinal A, Haser B, Sinha A, Halim I, Fasel D, Cuneo N, Thompson JJ, Verbitsky M, Cohn EG, Goldman J, Marder K, Klitzman RL, Orjuela MA, So YS, Fedotov A, Crew KD, Kiryluk K, Appelbaum PS, Weng C, Siegel K, Gharavi AG, Chung WK.

Genet Med. 2019 Apr 1. doi: 10.1038/s41436-019-0497-y. [Epub ahead of print] Erratum in: Genet Med. 2019 May 1;:.

PMID:
30930462
7.

Identifying Women at High Risk for Breast Cancer Using Data From the Electronic Health Record Compared With Self-Report.

Jiang X, McGuinness JE, Sin M, Silverman T, Kukafka R, Crew KD.

JCO Clin Cancer Inform. 2019 Mar;3:1-8. doi: 10.1200/CCI.18.00072.

8.

Association between body mass index and response to duloxetine for aromatase inhibitor-associated musculoskeletal symptoms in SWOG S1202.

Henry NL, Unger JM, Till C, Schott AF, Crew KD, Lew DL, Fisch MJ, Moinpour CM, Wade JL 3rd, Hershman DL.

Cancer. 2019 Jun 15;125(12):2123-2129. doi: 10.1002/cncr.32024. Epub 2019 Mar 12.

PMID:
30861098
9.

Automatic Genetic Risk Assessment Calculation Using Breast Cancer Family History Data from the EHR compared to Self-Report.

Sin M, McGuinness JE, Trivedi MS, Vanegas A, Silverman TB, Crew KD, Kukafka R.

AMIA Annu Symp Proc. 2018 Dec 5;2018:970-978. eCollection 2018.

10.

An Applied Framework in Support of Shared Decision Making about BRCA Genetic Testing.

Silverman TB, Kuperman GJ, Vanegas A, Sin M, Dimond J, Crew KD, Kukafka R.

AMIA Annu Symp Proc. 2018 Dec 5;2018:961-969. eCollection 2018.

11.

Pilot study of decision support tools on breast cancer chemoprevention for high-risk women and healthcare providers in the primary care setting.

Kukafka R, Fang J, Vanegas A, Silverman T, Crew KD.

BMC Med Inform Decis Mak. 2018 Dec 17;18(1):134. doi: 10.1186/s12911-018-0716-5.

12.

Neoadjuvant Chemotherapy Use for Nonmetastatic Breast Cancer at Five Public South African Hospitals and Impact on Time to Initial Cancer Therapy.

O'Neil DS, Nietz S, Buccimazza I, Singh U, Čačala S, Stopforth LW, Joffe M, Jacobson JS, Neugut AI, Crew KD, Ruff P, Cubasch H.

Oncologist. 2019 Jul;24(7):933-944. doi: 10.1634/theoncologist.2018-0535. Epub 2018 Dec 5.

PMID:
30518615
13.

Omega-3 fatty acid use for obese breast cancer patients with aromatase inhibitor-related arthralgia (SWOG S0927).

Shen S, Unger JM, Crew KD, Till C, Greenlee H, Gralow J, Dakhil SR, Minasian LM, Wade JL 3rd, Fisch MJ, Henry NL, Hershman DL.

Breast Cancer Res Treat. 2018 Dec;172(3):603-610. doi: 10.1007/s10549-018-4946-0. Epub 2018 Aug 29.

PMID:
30159789
15.

Study protocol: a cluster randomized controlled trial of web-based decision support tools for increasing BRCA1/2 genetic counseling referral in primary care.

Silverman TB, Vanegas A, Marte A, Mata J, Sin M, Ramirez JCR, Tsai WY, Crew KD, Kukafka R.

BMC Health Serv Res. 2018 Aug 13;18(1):633. doi: 10.1186/s12913-018-3442-x.

16.

Effect of Acupuncture vs Sham Acupuncture or Waitlist Control on Joint Pain Related to Aromatase Inhibitors Among Women With Early-Stage Breast Cancer: A Randomized Clinical Trial.

Hershman DL, Unger JM, Greenlee H, Capodice JL, Lew DL, Darke AK, Kengla AT, Melnik MK, Jorgensen CW, Kreisle WH, Minasian LM, Fisch MJ, Henry NL, Crew KD.

JAMA. 2018 Jul 10;320(2):167-176. doi: 10.1001/jama.2018.8907.

17.

Pre-surgical trial of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer: a New York Cancer Consortium trial.

Kalinsky K, Sparano JA, Zhong X, Andreopoulou E, Taback B, Wiechmann L, Feldman SM, Ananthakrishnan P, Ahmad A, Cremers S, Sireci AN, Cross JR, Marks DK, Mundi P, Connolly E, Crew KD, Maurer MA, Hibshoosh H, Lee S, Hershman DL.

Clin Transl Oncol. 2018 Nov;20(11):1474-1483. doi: 10.1007/s12094-018-1888-2. Epub 2018 May 7.

PMID:
29736694
18.

Neoadjuvant chemotherapy among patients treated for nonmetastatic breast cancer in a population with a high HIV prevalence in Johannesburg, South Africa.

Ruff P, Cubasch H, Joffe M, Rosenbaum E, Murugan N, Tsai MC, Ayeni O, Crew KD, Jacobson JS, Neugut AI.

Cancer Manag Res. 2018 Feb 9;10:279-286. doi: 10.2147/CMAR.S148317. eCollection 2018.

19.

A Randomized Multicenter Phase II Study of Docosahexaenoic Acid in Patients with a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease.

Gucalp A, Zhou XK, Cook ED, Garber JE, Crew KD, Nangia JR, Bhardwaj P, Giri DD, Elemento O, Verma A, Wang H, Lee JJ, Vornik LA, Mays C, Weber D, Sepeda V, O'Kane H, Krasne M, Williams S, Morris PG, Heckman-Stoddard BM, Dunn BK, Hudis CA, Brown PH, Dannenberg AJ.

Cancer Prev Res (Phila). 2018 Apr;11(4):203-214. doi: 10.1158/1940-6207.CAPR-17-0354. Epub 2018 Feb 16.

20.

Dynamic Diffuse Optical Tomography for Monitoring Neoadjuvant Chemotherapy in Patients with Breast Cancer.

Gunther JE, Lim EA, Kim HK, Flexman M, Altoé M, Campbell JA, Hibshoosh H, Crew KD, Kalinsky K, Hershman DL, Hielscher AH.

Radiology. 2018 Jun;287(3):778-786. doi: 10.1148/radiol.2018161041. Epub 2018 Feb 12.

21.

Factors Associated with False Positive Results on Screening Mammography in a Population of Predominantly Hispanic Women.

McGuinness JE, Ueng W, Trivedi MS, Yi HS, David R, Vanegas A, Vargas J, Sandoval R, Kukafka R, Crew KD.

Cancer Epidemiol Biomarkers Prev. 2018 Apr;27(4):446-453. doi: 10.1158/1055-9965.EPI-17-0009. Epub 2018 Jan 30.

22.

Two-Year Trends of Taxane-Induced Neuropathy in Women Enrolled in a Randomized Trial of Acetyl-L-Carnitine (SWOG S0715).

Hershman DL, Unger JM, Crew KD, Till C, Greenlee H, Minasian LM, Moinpour CM, Lew DL, Fehrenbacher L, Wade JL 3rd, Wong SF, Fisch MJ, Lynn Henry N, Albain KS.

J Natl Cancer Inst. 2018 Jun 1;110(6):669-676. doi: 10.1093/jnci/djx259.

23.

What Factors Influence Decision-Making about Breast Cancer Chemoprevention among High-Risk Women?

Crew KD.

Cancer Prev Res (Phila). 2017 Nov;10(11):609-611. doi: 10.1158/1940-6207.CAPR-17-0281. Epub 2017 Oct 4.

24.

Introducing a Comprehensive Informatics Framework to Promote Breast Cancer Risk Assessment and Chemoprevention in the Primary Care Setting.

Finkelstein J, Wood J, Crew KD, Kukafka R.

AMIA Jt Summits Transl Sci Proc. 2017 Jul 26;2017:58-67. eCollection 2017.

25.

Randomized trial of medroxyprogesterone acetate for the prevention of endometrial pathology from adjuvant tamoxifen for breast cancer: SWOG S9630.

Potkul RK, Unger JM, Livingston RB, Crew KD, Wilczynski SP, Salomon CG, Smith BL, Wong L, Campbell DL, Einspahr DE, Anderson GL, Hershman D, Goodman GE, Brown PH, Meyskens FL, Albain KS.

NPJ Breast Cancer. 2016 Aug 10;2:16024. doi: 10.1038/npjbcancer.2016.24. eCollection 2016.

26.

South African Breast Cancer and HIV Outcomes Study: Methods and Baseline Assessment.

Cubasch H, Ruff P, Joffe M, Norris S, Chirwa T, Nietz S, Sharma V, Duarte R, Buccimazza I, Čačala S, Stopforth LW, Tsai WY, Stavsky E, Crew KD, Jacobson JS, Neugut AI.

J Glob Oncol. 2017 Apr;3(2):114-124. doi: 10.1200/JGO.2015.002675.

27.

How do we increase uptake of tamoxifen and other anti-estrogens for breast cancer prevention?

Crew KD, Albain KS, Hershman DL, Unger JM, Lo SS.

NPJ Breast Cancer. 2017 May 19;3:20. doi: 10.1038/s41523-017-0021-y. eCollection 2017.

28.

Chemoprevention Uptake among Women with Atypical Hyperplasia and Lobular and Ductal Carcinoma In Situ.

Trivedi MS, Coe AM, Vanegas A, Kukafka R, Crew KD.

Cancer Prev Res (Phila). 2017 Aug;10(8):434-441. doi: 10.1158/1940-6207.CAPR-17-0100. Epub 2017 Jun 13.

29.

The Impact of Mental Illness on Uptake of Genetic Counseling for Hereditary Breast Cancer and Ovarian Cancer in a Multiethnic Cohort of Breast Cancer Patients.

Ackerman MG, Shapiro PA, Coe A, Trivedi MS, Crew KD.

Breast J. 2017 Sep;23(5):519-524. doi: 10.1111/tbj.12791. Epub 2017 Mar 21.

PMID:
28323373
30.

Usability Testing of a Web-Based Decision Aid for Breast Cancer Risk Assessment Among Multi-Ethnic Women.

Coe AM, Ueng W, Vargas JM, David R, Vanegas A, Infante K, Trivedi M, Yi H, Dimond J, Crew KD, Kukafka R.

AMIA Annu Symp Proc. 2017 Feb 10;2016:411-420. eCollection 2016.

31.

Population-Based Study of Attitudes toward BRCA Genetic Testing among Orthodox Jewish Women.

Tang EY, Trivedi MS, Kukafka R, Chung WK, David R, Respler L, Leifer S, Schechter I, Crew KD.

Breast J. 2017 May;23(3):333-337. doi: 10.1111/tbj.12736. Epub 2016 Nov 30.

PMID:
27900810
32.

Survivorship care plans and adherence to lifestyle recommendations among breast cancer survivors.

Greenlee H, Molmenti CL, Crew KD, Awad D, Kalinsky K, Brafman L, Fuentes D, Shi Z, Tsai WY, Neugut AI, Hershman DL.

J Cancer Surviv. 2016 Dec;10(6):956-963. Epub 2016 Apr 21.

PMID:
27100859
33.

Long-term Diet and Biomarker Changes after a Short-term Intervention among Hispanic Breast Cancer Survivors: The ¡Cocinar Para Su Salud! Randomized Controlled Trial.

Greenlee H, Ogden Gaffney A, Aycinena AC, Koch P, Contento I, Karmally W, Richardson JM, Shi Z, Lim E, Tsai WY, Santella RM, Blaner WS, Clugston RD, Cremers S, Pollak S, Sirosh I, Crew KD, Maurer M, Kalinsky K, Hershman DL.

Cancer Epidemiol Biomarkers Prev. 2016 Nov;25(11):1491-1502. Epub 2016 Jul 26.

34.

Proteomic modulation in breast tumors after metformin exposure: results from a "window of opportunity" trial.

Kalinsky K, Zheng T, Hibshoosh H, Du X, Mundi P, Yang J, Refice S, Feldman SM, Taback B, Connolly E, Crew KD, Maurer MA, Hershman DL.

Clin Transl Oncol. 2017 Feb;19(2):180-188. doi: 10.1007/s12094-016-1521-1. Epub 2016 Jun 15.

PMID:
27305912
35.

Randomized sham-controlled pilot trial of weekly electro-acupuncture for the prevention of taxane-induced peripheral neuropathy in women with early stage breast cancer.

Greenlee H, Crew KD, Capodice J, Awad D, Buono D, Shi Z, Jeffres A, Wyse S, Whitman W, Trivedi MS, Kalinsky K, Hershman DL.

Breast Cancer Res Treat. 2016 Apr;156(3):453-464. doi: 10.1007/s10549-016-3759-2. Epub 2016 Mar 25.

36.

Barriers to Recruitment and Adherence in a Randomized Controlled Diet and Exercise Weight Loss Intervention Among Minority Breast Cancer Survivors.

Aycinena AC, Valdovinos C, Crew KD, Tsai WY, Mata JM, Sandoval R, Hershman D, Greenlee H.

J Immigr Minor Health. 2017 Feb;19(1):120-129. doi: 10.1007/s10903-015-0310-1.

PMID:
26801931
37.

Interaction between polyunsaturated fatty acids and genetic variants in relation to breast cancer incidence.

Khankari NK, Bradshaw PT, Steck SE, He K, Olshan AF, Ahn J, Terry MB, Crew KD, Teitelbaum SL, Neugut AI, Santella RM, Gammon MD.

J Cancer Epidemiol Prev (iMedPub). 2016;1(1). pii: 2. Epub 2016 Dec 30.

38.

Identifying Predictors of Taxane-Induced Peripheral Neuropathy Using Mass Spectrometry-Based Proteomics Technology.

Chen EI, Crew KD, Trivedi M, Awad D, Maurer M, Kalinsky K, Koller A, Patel P, Kim Kim J, Hershman DL.

PLoS One. 2015 Dec 28;10(12):e0145816. doi: 10.1371/journal.pone.0145816. eCollection 2015.

39.

Methods to Standardize a Multicenter Acupuncture Trial Protocol to Reduce Aromatase Inhibitor-related Joint Symptoms in Breast Cancer Patients.

Greenlee H, Crew KD, Capodice J, Awad D, Jeffres A, Unger JM, Lew DL, Hansen LK, Meyskens FL Jr, Wade JL 3rd, Hershman DL.

J Acupunct Meridian Stud. 2015 Jun;8(3):152-8. doi: 10.1016/j.jams.2015.03.006. Epub 2015 Apr 23.

40.

Addressing barriers to uptake of breast cancer chemoprevention for patients and providers.

Crew KD.

Am Soc Clin Oncol Educ Book. 2015:e50-8. doi: 10.14694/EdBook_AM.2015.35.e50.

41.

Randomized Multicenter Placebo-Controlled Trial of Omega-3 Fatty Acids for the Control of Aromatase Inhibitor-Induced Musculoskeletal Pain: SWOG S0927.

Hershman DL, Unger JM, Crew KD, Awad D, Dakhil SR, Gralow J, Greenlee H, Lew DL, Minasian LM, Till C, Wade JL 3rd, Meyskens FL, Moinpour CM.

J Clin Oncol. 2015 Jun 10;33(17):1910-7. doi: 10.1200/JCO.2014.59.5595. Epub 2015 May 4.

42.

Breast Cancer Chemoprevention among High-risk Women and those with Ductal Carcinoma In Situ.

Reimers LL, Sivasubramanian PS, Hershman D, Terry MB, Greenlee H, Campbell J, Kalinsky K, Maurer M, Jayasena R, Sandoval R, Alvarez M, Crew KD.

Breast J. 2015 Jul-Aug;21(4):377-86. doi: 10.1111/tbj.12418. Epub 2015 Apr 16.

43.

Dietary modifications, weight loss, and changes in metabolic markers affect global DNA methylation in Hispanic, African American, and Afro-Caribbean breast cancer survivors.

Delgado-Cruzata L, Zhang W, McDonald JA, Tsai WY, Valdovinos C, Falci L, Wang Q, Crew KD, Santella RM, Hershman DL, Greenlee H.

J Nutr. 2015 Apr;145(4):783-90. doi: 10.3945/jn.114.202853. Epub 2015 Feb 4.

44.

Atypical hyperplasia of the breast.

Reimers LL, Crew KD, Terry MB.

N Engl J Med. 2015 Mar 26;372(13):1270-1. doi: 10.1056/NEJMc1501046. No abstract available.

PMID:
25806931
45.

Genetic polymorphisms in DNA repair and oxidative stress pathways may modify the association between body size and postmenopausal breast cancer.

McCullough LE, Eng SM, Bradshaw PT, Cleveland RJ, Steck SE, Terry MB, Shen J, Crew KD, Rossner P Jr, Ahn J, Ambrosone CB, Teitelbaum SL, Neugut AI, Santella RM, Gammon MD.

Ann Epidemiol. 2015 Apr;25(4):263-9. doi: 10.1016/j.annepidem.2015.01.009. Epub 2015 Jan 24.

46.

Safety, Feasibility, and Biomarker Effects of High-Dose Vitamin D Supplementation Among Women at High Risk for Breast Cancer.

Crew KD, Xiao T, Thomas PS, Terry MB, Maurer M, Kalinsky K, Feldman S, Brafman L, Refice SR, Hershman DL.

Int J Food Sci Nutr Diet. 2015;2015(Suppl 1):1-16. doi: 10.19070/2326-3350-SI01001. Epub 2015 Feb 23.

47.

Barriers and Facilitators to Patient-Provider Communication When Discussing Breast Cancer Risk to Aid in the Development of Decision Support Tools.

Yi H, Xiao T, Thomas PS, Aguirre AN, Smalletz C, Dimond J, Finkelstein J, Infante K, Trivedi M, David R, Vargas J, Crew KD, Kukafka R.

AMIA Annu Symp Proc. 2015 Nov 5;2015:1352-60. eCollection 2015.

48.

Vitamin D-related gene polymorphisms, plasma 25-hydroxyvitamin D, and breast cancer risk.

Reimers LL, Crew KD, Bradshaw PT, Santella RM, Steck SE, Sirosh I, Terry MB, Hershman DL, Shane E, Cremers S, Dworakowski E, Teitelbaum SL, Neugut AI, Gammon MD.

Cancer Causes Control. 2015 Feb;26(2):187-203. doi: 10.1007/s10552-014-0497-9. Epub 2014 Nov 25.

49.

Increased expression of tumor proliferation genes in Hispanic women with early-stage breast cancer.

Kalinsky K, Lim EA, Andreopoulou E, Desai AM, Jin Z, Tu Y, Hibshoosh H, Wang A, Greenlee H, Crew KD, Maurer M, Sparano JA, Hershman DL.

Cancer Invest. 2014 Nov;32(9):439-44. doi: 10.3109/07357907.2014.958232. Epub 2014 Sep 25.

50.

Mammographic density and serum 25-hydroxyvitamin D levels.

Crew KD, Campbell J, Reynolds D, Fulton L, Flom JD, Liao Y, Tehranifar P, Terry MB.

Nutr Metab (Lond). 2014 Apr 17;11:18. doi: 10.1186/1743-7075-11-18. eCollection 2014.

Supplemental Content

Support Center